Endovasc Receives Issue Notification for U.S. Patent Protecting its Muscle Mass Technology.HOUSTON -- Endovasc Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : EVSC EVSC Evansville Vanderburgh School Corporation , OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). : EVSD), announced today that the Company has received a patent issue notification from the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property for the patent application entitled "Development of Muscle Mass in a Mammal." Issuance of the patent is expected within the next few weeks. Diane Dottavio, Ph.D., Endovasc's Chairman and Chief Executive Officer, commented, "We are extremely pleased to receive this patent issue notification regarding the protection of our muscle mass technology. The issue notification means this technology is now protected in the United States. The company has also filed for patent protection in Europe, Asia and other regions of the world. We expect patents to be granted upon completion of the patent application examination process." Endovasc's wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. , Nutraceutical Development Corporation, licensed the technology to Basic Research to develop and market a non-steroid supplement which utilizes the Company's muscle mass technology. Endothil-CR is currently available at GNC GNC General Nutrition Centers GNC Gas Natural Comprimido (Argentina) GNC Guidance, Navigation, and Control GNC Grand National Championship (ATV racing) GNC Global Navigation Chart stores nationwide or on the World Wide Web at www.Endothil.com. About Endovasc, Inc. Endovasc, Inc is focused on developing and commercializing drug candidates in the areas of cardiovascular and metabolic medicine. Endovasc is organized as a business development company, operating through the following subsidiaries: Liprostin Inc., which holds the intellectual property for a liposomal based treatment to increase circulation and reduce leg pain in patients suffering from vascular disease; Prostent, Inc., which is developing urinary tract stent coating technology; and Nutraceutical Development Corporation. For more information about Endovasc, please visit www.endovasc.com. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. : Except for the historical information contained herein, this news release contains forward-looking statements that involve risk and uncertainties, including clinical results, the timely availability and acceptance of new products, the impact of competitive products and pricing, the availability of funding from partners or capital markets, and the management of growth, as well as the other risks detailed from time to time in Endovasc's Exchange Commission (SEC) Filings, including the company's Annual Report on Form 10-KSB, and quarterly reports on Form 10-QSB. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion